Ibrutinib is a well-tolerated and safe drug, but the concern about its collateral effects on other kinases besides BTK, associated with a higher risk of bleeding (mostly grade 1–2 events in the clinical practice) and cardiovascular events (atrial fibrillation and hypertension) led to the development of new generation BTKi with reduced off-target effects. This evidence concerns the gene BTK and hypertensive disorder.